You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 282 No. 18, November 10, 1999 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Special Communication
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Journalology/ Peer Review/ Authorship
 •Quality of Care
 •Evidence-Based Medicine
 •Statistics and Research Methods
 •Randomized Controlled Trial
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Appendix: Problems in the Design and Reporting of Trials of Antifungal Agents Encountered During Meta-analysis

Helle Krogh Johansen, MD, DMSc; Peter C. Gøtzsche, MD, DMSc

JAMA. 1999;282:1756-1757.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

APPENDIX

We identified 12 relevant reports,1-12 of which 3 were subsequently excluded. A trial in which only 12 patients received nystatin had failed due to serious problems with compliance9; another reported only the number of "Candida-free" days (which was 18 for both nystatin and placebo)10; the third report was a duplicate publication.11 Of the 9 included trials, 1 was published as an abstract only.8

The drugs were given prophylactically in 7 trials and as treatment in 2.6, 12 Acute leukemia was the most common disease in 6 trials; 1 trial concerned patients receiving a liver transplant7; 1, critically ill surgical and trauma patients3; and 1, patients with acquired immunodeficiency syndrome.12 Nystatin was compared with placebo in 3 trials1-3 and with fluconazole in 64-8,12; all drugs were given orally. In total, 537 patients received nystatin, 147 . . . [Full Text of this Article]

Author Affiliations: The Nordic Cochrane Centre, Rigshospitalet, Copenhagen, Denmark.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Problems in the Design and Reporting of Trials of Antifungal Agents Encountered During Meta-analysis
Helle Krogh Johansen and Peter C. Gøtzsche
JAMA. 1999;282(18):1752-1759.
ABSTRACT | FULL TEXT  

Fair Conduct and Fair Reporting of Clinical Trials
Drummond Rennie
JAMA. 1999;282(18):1766-1768.
EXTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1999 American Medical Association. All Rights Reserved.